Vimta Labs Ltd

Vimta Labs Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Vimta Labs Ltd

₹ 485 0.87%
02 Jul - close price
vimta.com BSE: 524394 NSE: VIMTALABS
About

Vimta Labs Limited is testing food and drugs. It also does contract research for clinical research and pre-clinical studies provider in India. It provides analytical, clinical and preclinical services to life sciences industries; quality and safety testing for food and beverage industries; and environment services to a wide spectrum of industries. [1][2]

Key Points

Services
The company deals in drug life cycle management, development and discovery support services, clinical research, central lab, and cGMP analytical services for pharmaceutical and biopharmaceutical companies.
It also provides food testing and analytical development services to support manufacturers, processors, farmers, retailers, traders, exporters & regulators, and EMI/EMC testing for electronic and electrical products. [1]

Website BSE NSE
  • Market Cap ₹ 1,075 Cr.
  • Current Price ₹ 485
  • High / Low ₹ 623 / 385
  • Stock P/E 28.0
  • Book Value ₹ 143
  • Dividend Yield 0.41 %
  • ROCE 16.8 %
  • ROE 12.9 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company is almost debt free.

Cons

  • The company has delivered a poor sales growth of 8.03% over past five years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Healthcare Industry: Miscellaneous

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
59 61 75 67 74 79 79 76 81 82 72 80 78
43 44 55 46 51 55 54 55 57 58 57 59 55
Operating Profit 17 17 20 20 23 24 25 21 24 24 15 21 24
OPM % 28% 27% 26% 31% 31% 30% 32% 27% 29% 29% 21% 26% 30%
0 0 -1 1 0 1 1 1 1 1 2 1 0
Interest 1 0 0 0 1 1 1 1 0 0 1 1 1
Depreciation 6 5 5 6 7 7 8 8 8 8 9 9 8
Profit before tax 10 11 13 15 16 17 18 14 16 16 8 13 16
Tax % 26% 26% 26% 25% 27% 27% 26% 27% 23% 25% 25% 25% 24%
8 8 10 12 12 12 13 10 12 12 6 9 12
EPS in Rs 3.51 3.67 4.30 5.23 5.37 5.44 5.91 4.50 5.54 5.25 2.67 4.27 5.32
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
109 127 116 138 154 183 213 181 209 276 315 313
88 101 99 119 127 138 155 151 156 196 222 229
Operating Profit 21 26 17 19 27 45 58 30 53 80 94 84
OPM % 19% 20% 15% 14% 18% 25% 27% 17% 25% 29% 30% 27%
1 3 1 1 1 1 2 3 1 0 3 4
Interest 3 2 1 1 2 5 5 4 2 2 3 2
Depreciation 15 9 11 10 10 16 20 21 23 23 31 34
Profit before tax 4 18 7 8 17 26 35 8 28 55 64 52
Tax % 4% 25% 24% 23% 36% 36% 28% 17% 25% 26% 26% 25%
4 13 5 6 11 16 25 7 21 41 47 39
EPS in Rs 1.90 5.99 2.29 2.91 4.79 7.43 11.45 3.13 9.62 18.57 21.37 17.51
Dividend Payout % 32% 33% 44% 34% 0% 27% 17% 0% 21% 11% 9% 11%
Compounded Sales Growth
10 Years: 9%
5 Years: 8%
3 Years: 14%
TTM: -1%
Compounded Profit Growth
10 Years: 11%
5 Years: 9%
3 Years: 22%
TTM: -18%
Stock Price CAGR
10 Years: 15%
5 Years: 23%
3 Years: 22%
1 Year: 19%
Return on Equity
10 Years: 12%
5 Years: 14%
3 Years: 17%
Last Year: 13%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity Capital 4 4 4 4 4 4 4 4 4 4 4 4
Reserves 108 116 118 122 132 148 167 169 190 229 276 312
12 7 4 26 44 40 26 32 30 19 15 19
21 22 21 23 42 40 40 39 49 54 65 61
Total Liabilities 145 149 146 176 222 232 237 245 273 306 360 396
93 90 88 88 88 140 135 131 128 162 168 163
CWIP 0 2 0 6 53 0 4 2 17 0 12 59
Investments 0 0 0 0 0 0 0 6 6 6 6 6
51 57 58 82 80 92 99 105 122 138 174 168
Total Assets 145 149 146 176 222 232 237 245 273 306 360 396

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
16 17 15 -1 24 33 39 24 37 59 87 59
-4 -8 -8 -16 -39 -24 -16 -20 -32 -38 -57 -75
-11 -8 -9 19 13 -8 -23 -1 -5 -16 -11 -2
Net Cash Flow 1 0 -1 2 -2 1 1 3 1 5 19 -17

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 87 81 82 100 101 111 100 117 128 102 93 101
Inventory Days 165 175 158 213 183 209 199 191 140 115 187 185
Days Payable 147 87 66 77 184 148 115 114 139 81 119 61
Cash Conversion Cycle 105 169 174 236 100 172 184 194 128 136 160 224
Working Capital Days 88 84 120 126 68 88 87 100 116 96 84 102
ROCE % 6% 16% 6% 7% 11% 17% 21% 6% 14% 24% 24% 17%

Shareholding Pattern

Numbers in percentages

1 Recently
Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
37.46% 37.46% 37.46% 37.46% 37.46% 37.46% 37.26% 37.25% 37.23% 37.00% 36.98% 36.92%
0.00% 0.00% 0.19% 0.36% 0.35% 0.49% 2.28% 2.25% 2.72% 2.74% 2.88% 5.13%
0.11% 1.40% 1.91% 1.96% 2.01% 2.04% 2.13% 2.14% 2.14% 1.50% 1.49% 1.50%
62.43% 61.14% 60.44% 60.22% 60.18% 60.02% 58.35% 58.37% 57.92% 58.75% 58.65% 56.45%
No. of Shareholders 20,92819,94719,19418,33218,10618,28318,91617,16217,43918,42919,95718,550

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls